

**MINI-FOCUS ISSUE: AMYLOIDOSIS****ORIGINAL RESEARCH**

# Low QRS Voltages in Cardiac Amyloidosis

## Clinical Correlates and Prognostic Value



Alberto Cipriani, MD,<sup>a,\*</sup> Laura De Michieli, MD,<sup>a,\*</sup> Aldostefano Porcari, MD, FISC,<sup>b</sup> Luca Licchelli, MD,<sup>a</sup> Giulio Sinigiani, MD,<sup>a</sup> Giacomo Tini, MD,<sup>c</sup> Mattia Zampieri, MD,<sup>d</sup> Eugenio Sessarego, MD,<sup>e</sup> Alessia Argirò, MD,<sup>d</sup> Carlo Fumagalli, MD,<sup>d</sup> Monica De Gaspari, MD,<sup>a</sup> Roberto Licordari, MD,<sup>f</sup> Domitilla Russo, MD,<sup>c</sup> Gianluca Di Bella, MD,<sup>f</sup> Federico Perfetto, MD,<sup>d,g</sup> Camillo Autore, MD,<sup>c</sup> Beatrice Musumeci, MD,<sup>c</sup> Marco Canepa, MD,<sup>e,h</sup> Marco Merlo, MD,<sup>b</sup> Gianfranco Sinagra, MD, FESC,<sup>b</sup> Dario Gregori, MD,<sup>a</sup> Sabino Iliceto, MD,<sup>a</sup> Martina Perazzolo Marra, MD, PhD,<sup>a</sup> Francesco Cappelli, MD,<sup>d,g,†</sup> Claudio Rapezzi, MD<sup>i,j,†</sup>

**ABSTRACT**

**BACKGROUND** Low QRS voltages (LQRSVs) are a common electrocardiographic feature in patients with light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) cardiac amyloidosis (CA).

**OBJECTIVES** The aim of this study was to identify clinical and echocardiographic correlates of LQRSV and to investigate their prognostic significance in patients with CA.

**METHODS** This was a multicenter, retrospective study performed in 6 CA referral centers including consecutive patients with AL and ATTR CA. LQRSVs were defined as a QRS amplitude  $\leq 5$  mm (0.5 mV) in all peripheral leads. The study outcome was cardiovascular (CV) mortality.

**RESULTS** Overall, 411 (AL CA:  $n = 120$ , ATTR CA:  $n = 291$ ) patients were included. LQRSVs were present in 66 (55%) patients with AL CA and 103 (35%) with ATTR CA ( $P < 0.001$ ). In AL CA, LQRSVs were independently associated with younger age ( $P = 0.015$ ), higher New York Heart Association functional class ( $P = 0.016$ ), and natriuretic peptides ( $P = 0.041$ ); in ATTR CA, LQRSVs were independently associated with pericardial effusion ( $P = 0.008$ ) and lower tricuspid annulus peak systolic excursion ( $P = 0.038$ ). During a median follow-up of 33 months (Q1-Q3: 21-46), LQRSVs independently predicted CV death in both AL CA (HR: 1.76; 95% CI: 2.41-10.18;  $P = 0.031$ ) and ATTR CA (HR: 2.64; 95% CI: 1.82-20.17;  $P = 0.005$ ). Together with the National Amyloidosis Centre (NAC) staging, LQRSVs provided incremental prognostic value in ATTR CA (AUC for NAC model: 0.83 [95% CI: 0.77-0.89]; AUC for NAC + LQRSV model: 0.87 [95% CI: 0.81-0.93];  $P = 0.040$ ).

**CONCLUSIONS** LQRSVs are common but not ubiquitous in CA; they are more frequent in AL CA than in ATTR CA. LQRSVs reflect an advanced disease stage and independently predict CV death. In ATTR CA, LQRSVs can provide incremental prognostic accuracy over the NAC staging system in patients with intermediate risk. (J Am Coll Cardiol CardioOnc 2022;4:458-470) © 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

From the <sup>a</sup>Department of Cardiac, Thoracic and Vascular Sciences and Public Health, University of Padua, Padua, Italy; <sup>b</sup>Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina, University of Trieste, Trieste, Italy; <sup>c</sup>Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy; <sup>d</sup>Tuscan Regional Amyloidosis Centre, Careggi University Hospital, Florence, Italy; <sup>e</sup>Department of Internal Medicine, University of Genova, Genova, Italy; <sup>f</sup>Department of Cardiology, University of Messina, Messina, Italy; <sup>g</sup>Cardiomyopathy Unit, Careggi University Hospital,

Cardiac amyloidosis (CA) is an increasingly recognized cause of cardiovascular morbidity and mortality.<sup>1-3</sup> It is characterized by extracellular myocardial infiltration of amyloid fibrils, mostly derived from either wild-type (ATTR-wt) or variant forms of the transthyretin (ATTR-v) protein or from monoclonal immunoglobulin light chain amyloidosis (AL).<sup>4</sup> Two main mechanisms of tissue and organ damage are known: chronic infiltration and acute proteotoxic effect of circulating precursors and nonamyloid aggregates. The latter is particularly evident and documented in AL but has also been shown in ATTR-v and ATTR-wt.<sup>5</sup> Despite a common cardiomyopathy phenotype, characterized by increased left ventricular (LV) mass and stiffness and restrictive hemodynamics, AL- and transthyretin amyloidosis (ATTR)-CA have different clinical profiles, courses, and outcomes, which are usually more severe in AL CA.<sup>6</sup>

The diagnosis of CA relies on invasive or noninvasive criteria aimed at demonstrating amyloid fibrils within the myocardium.<sup>7</sup> Although not included in these criteria, a 12-lead electrocardiogram (ECG) is an essential test in the diagnostic evaluation of patients with suspected CA. In particular, ECG can raise or support the clinical suspicion of CA by revealing various red flags, such as atrioventricular conduction disturbances, pseudoinfarction patterns, and low QRS voltages (LQRSV).<sup>7-9</sup> The most striking electrocardiographic abnormality in patients with CA is the reduction of QRS voltages, particularly in the limb leads, and the disproportion between QRS voltages and left ventricular (LV) thickness at echocardiography.<sup>10</sup> LQRSVs, which are described also in multiple noncardiac (obesity and emphysema) and cardiac disorders (pericardial effusion and arrhythmogenic cardiomyopathy),<sup>11</sup> can be observed in up to 60% of patients with CA, more frequently in AL,<sup>6</sup> and may hypothetically reflect the burden of amyloid infiltration in the heart. Nevertheless, the underlying structural correlates of LQRSV in both AL- and ATTR CA remains to be clearly defined as well as their prognostic meaning. Thus, the present study was designed to assess the prevalence of LQRSVs in the different forms of CA, to identify their clinical and

echocardiographic correlates, and to investigate their prognostic significance in a large multicenter study of patients with CA.

## METHODS

This is a multicenter, retrospective, observational study performed in 6 referral centers for CA: Padua (Padua University Hospital), Trieste (Cattinara Hospital), Rome (Sant'Andrea Hospital), Florence (Careggi Hospital), Genoa (San Martino Hospital), and Messina (Messina University Hospital). The local regional Institutional Review Board approved the study, and the participating centers obtained local Institutional Review Board approvals for the collection of anonymous data. The study was conducted according to the Declaration of Helsinki, and informed consent was obtained according to the local review board policies. Details on the study population and methods have been published previously.<sup>12</sup>

## STUDY DESIGN AND STUDY POPULATION.

Consecutive patients with AL- and ATTR CA diagnosed at participating centers between January 1, 2017, and December 31, 2020, were included in the analysis. The diagnosis of AL and ATTR CA was confirmed by tissue biopsy or through established noninvasive criteria according to the latest European Society of Cardiology diagnostic guidelines.<sup>8</sup> Genetic testing was performed in all patients with ATTR CA to identify mutations in the *TTR* gene. Patients with AL CA were treated with chemotherapy and/or autologous stem cell transplant according to specific guidelines.<sup>13</sup> Patients were systematically followed up from the date of the first cardiologic evaluation at participating referral centers (baseline) until the end of the study period (ie, October 31, 2021). The clinical data recorded within  $\pm 1$  month from a baseline visit included all of the following: 1) clinical examination including ongoing therapy; 2) ECG; and 3) echocardiography. The same data were collected from the last visit available for each patient during the study period.

## ABBREVIATIONS AND ACRONYMS

<b>AL</b>	= light chain amyloidosis
<b>ATTR</b>	= transthyretin amyloidosis
<b>ATTR-wt</b>	= wild-type transthyretin
<b>ATTR-v</b>	= variant transthyretin
<b>AUC</b>	= area under the curve
<b>BNP</b>	= B-type natriuretic peptide
<b>CA</b>	= cardiac amyloidosis
<b>CMR</b>	= cardiac magnetic resonance
<b>CV</b>	= cardiovascular
<b>ECG</b>	= electrocardiogram
<b>LQRSV</b>	= low QRS voltages
<b>LV</b>	= left ventricle
<b>LVEDD</b>	= left ventricular end-diastolic diameter
<b>NAC</b>	= National Amyloidosis Centre
<b>NT-proBNP</b>	= N-terminal pro-B-type natriuretic peptide
<b>NYHA</b>	= New York Heart Association
<b>ROC</b>	= receiver-operating characteristic
<b>RV</b>	= right ventricular
<b>TAPSE</b>	= tricuspid annulus peak systolic excursion

University of Florence, Florence, Italy; <sup>b</sup>Cardiovascular Unit, Department of Internal Medicine, University of Genova, Ospedale Policlinico San Martino Istituto Ricovero e Cura a Carattere Scientifico, Genova, Italy; <sup>c</sup>Cardiothoracic Department, University of Ferrara, Ferrara, Italy; and the <sup>d</sup>Maria Cecilia Hospital, Gruppo Villa Maria Care and Research, Cotignola, Ravenna, Italy. \*Drs Cipriani and De Michieli are co-first authors. †Dr Cappelli and Prof Rapezzi share the last authorship. ‡Dr Rapezzi is deceased. The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

Patients with characteristics likely to alter electrocardiographic voltage measurements such as severe pericardial effusion (>20 mm), chronic obstructive lung disease with emphysema, body mass index >35 kg/m<sup>2</sup>, and paced rhythm were excluded from this analysis.

**ELECTROCARDIOGRAPHY.** Twelve-lead ECGs were acquired in the supine position with the limb leads placed at the wrists and ankles at standard speed (25 mm/s) and amplification (10 mm/mV). We reviewed them collecting the following data: electrocardiographic machine filter setting; rhythm; PR interval; QRS voltages and duration; depolarization and repolarization abnormalities. Specifically, first-degree atrioventricular block was defined as a PR interval >200 milliseconds; left anterior hemiblock, right bundle branch block, and left bundle branch block as previously defined<sup>14</sup>; and T-wave inversion as  $\geq 0.1$  mV in depth in  $\geq 2$  contiguous leads in the absence of right bundle branch block/left bundle branch block. The broadest definition for LQRSV was applied (ie, QRS amplitude  $\leq 5$  mm [0.5 mV] in all peripheral leads, including both negative and positive components). We applied this definition throughout this work given its previous consistent use,<sup>6,7,15-20</sup> high specificity,<sup>15</sup> and practical applicability in a multicentric project to ensure high reliability and reproducibility between centers. Limb, precordial, and total QRS scores were also calculated by the sum of the Q, R, and S height, each taken as the absolute value in millimeters (1 mm = 0.1 mV), in all 6 limb and precordial leads.<sup>6,15</sup>

**ECHOCARDIOGRAPHY.** Echocardiographic images stored on the electronic databases of the participating centers were systematically reviewed and postprocessed for this analysis. All echocardiographic parameters were measured according to the most recent American Society of Echocardiography/European Association of Cardiovascular Imaging guidelines.<sup>21</sup> LV mass and LV mass indexed to body surface area were calculated using the Devereux formula, relative wall thickness as  $2 \times$  posterior wall thickness in diastole/LV end-diastolic diameter ( $2 \times$  posterior wall thickness in diastole/left ventricular end-diastolic diameter [LVEDD]), and myocardial volume as LV mass/1.05. Left ventricular ejection fraction was calculated with the biplane Simpson method from volumes acquired in both the 4- and 2-chamber views. Tricuspid annulus peak systolic excursion (TAPSE) was assessed with M-mode in the 4-chamber view, and systolic pulmonary artery pressure was estimated based on tricuspid regurgitation velocity and estimated right atrial pressure. The LV filling pattern

(E-wave, A-wave, and deceleration time) was evaluated with pulsed Doppler in the 4-chamber view. The lateral mitral annulus velocity (e' wave) was assessed with tissue Doppler in the 4-chamber view; the ratio between LV early diastolic filling and lateral mitral annulus velocity (E/e') was calculated.<sup>22</sup> The voltage-to-mass ratio was calculated as the limb or total QRS score divided by LV mass indexed to body surface area.

**NUCLEAR MEDICINE.** Cardiac scintigraphy was performed with different bone tracers (<sup>99m</sup>Tc-3,3-diphosphono-1,2-propanodicarboxylic acid and <sup>99m</sup>Tc-hydroxymethylene diphosphonate) according to each center's local practice. A semiquantitative score for the left ventricle was obtained based on the results of planar images as previously described by Perugini *et al.*<sup>23</sup>

**BIOMARKERS.** Levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) and B-type natriuretic peptide (BNP) were measured according to local laboratories. High BNP levels were defined as NT-proBNP >1,800 ng/L or BNP >400 ng/L for AL<sup>24</sup> and NT-proBNP >3,000 ng/L or BNP >250 ng/L for ATTR.<sup>25,26</sup> The National Amyloidosis Centre (NAC) ATTR staging from Gillmore *et al.*<sup>25</sup> was measured in ATTR patients, and 3 classes were identified using biomarker cutoffs of 45 mL/min/1.73 m<sup>2</sup> for estimated glomerular filtration rate (standard Modified Diet in Renal Disease formula) and 3,000 ng/L for NT-proBNP (or 250 ng/L for BNP).

**OUTCOMES.** Survival analysis was calculated with day 1 being the first day of evaluation and electrocardiographic recording at the referral center rather than the day of diagnosis in order to avoid any time referral bias. We collected data regarding overall mortality and cardiovascular (CV) mortality over the study period. However, because a non-negligible proportion of patients died because of severe acute respiratory syndrome coronavirus 2 infection, we decided to perform our survival analysis including only CV mortality as an outcome in order to avoid biases related to the coronavirus disease-2019 pandemic.

**STATISTICAL ANALYSIS.** Baseline characteristics are expressed as mean  $\pm$  SD when normally distributed (as assessed by the Shapiro-Wilk test) or as median with 25th and 75th percentiles (Q1-Q3) when non-normally distributed. Variables with normal distribution and equal variances were compared with the Student's *t*-test, and variables with unequal variances were compared with Welch's *t*-test. Variables with non-normal distribution were compared using the Wilcoxon rank sum test. Categorical variables were

expressed as absolute numbers and percentages and were compared using the chi-square test or Fisher exact test when appropriate.

Because of the potential high collinearity among covariates and the low ratio between the number of observations and covariates, the multivariable analysis has been based on a penalized generalized linear model (GLM). This class of models includes the lasso or elastic net penalty at a grid of values for the regularization parameter lambda.<sup>27</sup> The optimal lambda value was derived via 20-fold cross-validation. LQRSV status was modeled using a logit link in the binomial family of GLM, whereas CV mortality was modeled using a Cox proportional hazard specification of the penalized regression.<sup>28</sup> The approximate *P* values and CIs for the penalized regression were derived.<sup>28</sup> Model results were presented as ORs or HRs and the corresponding 95% CIs.

The receiver-operating characteristic (ROC) curves were used to evaluate the accuracy of survival prediction between multiple measures of QRS voltages, including the peripheral QRS score, precordial QRS score, total QRS score, and limb and total voltage-to-mass ratios. The maximum value of the Youden index was then used as the best cutoff to calculate sensitivity and specificity.

The log-rank test and Kaplan-Meier survival analysis were used to explore survival in groups with and without LQRSV. As a sensitivity analysis, competing risk between CV and all-cause mortality was explored using the Fine and Gray model,<sup>29</sup> and the cause-specific cumulative incidence functions were estimated.

The possible incremental prognostic role of LQRSV in patients with ATTR CA, when combined with NAC ATTR staging, was first explored by means of the log-rank test and Kaplan-Meier survival analysis and the time-dependent area under the curve (AUC) of the corresponding ROCs.<sup>30</sup> Then, a formal evaluation on the incremental value of LQRSV to NAC was conducted by estimating the net reclassification improvement index.<sup>31</sup> We defined a *P* value <0.05 as statistically significant. All statistical analyses were performed using R System (R Foundation for Statistical Computing) and the IBM SPSS Statistics 27.0 package.

## RESULTS

Of the 455 patients diagnosed with CA in our centers during the study period, 411 (AL: *n* = 120, ATTR: *n* = 291) fulfilled the inclusion criteria and were included in this analysis (Supplemental Figure 1). Among ATTR, 57 patients were diagnosed with

ATTR-v (further description of *TTR* variants is presented in the Supplemental Results).

At the baseline visit, overall 74% of patients were in sinus rhythm, 26% were in atrial fibrillation or atrial flutter, and 6% had a backup pacing cardiac device (2% implantable cardioverter-defibrillator and 4% pacemaker). Most patients were in New York Heart Association (NYHA) functional class I or II (65% in the AL amyloidosis group and 78% in the ATTR amyloidosis group). Among ATTR CA, 21 of 291 (7%) patients, all hereditary forms, were on antiamyloid therapy because of familial amyloid polyneuropathy.

The electrocardiographic machines' filter setting was deemed appropriate given that in 91% patients low-pass filters of 150 Hz were used. Low QRS voltages at ECG were detected in 169 patients with CA (41%), 66 (55%) with AL CA and 103 (35%) patients with ATTR CA (*P* < 0.001). The limb and total voltage-to-mass ratios were lower in ATTR CA than AL CA, although they were not significantly different (0.19 vs 0.21 [*P* = 0.24] and 0.64 vs 0.70 [*P* = 0.058], respectively). LQRSVs were more common in younger patients (72 ± 11 vs 75 ± 10; *P* < 0.001) with NYHA class III and higher NT-proBNP/BNP values; more frequent pericardial effusions; and decreased LVEDD, myocardial volume, and TAPSE. Further analysis and description about the differences of patients with AL-CA versus ATTR CA and with LQRSV versus without LQRSV are presented in Supplemental Table 1.

### CLINICAL PREDICTORS OF LQRSVs IN CARDIAC AMYLOIDOSIS.

Differences in clinical and echocardiographic features of patients with AL CA and ATTR CA according to the presence of LQRSV are reported in Table 1. In both groups, the presence of LQRSV was not associated with body mass index. In patients with AL CA, LQRSV were more frequently observed in those with younger age (*P* = 0.046), NYHA functional class III (*P* < 0.001), anterior pseudoinfarction QRS pattern (*P* < 0.001), high NT-proBNP/BNP values (*P* = 0.009), greater posterior wall thickness in diastole (*P* = 0.036), diastolic interventricular septum thickness (*P* = 0.019), relative wall thickness (*P* < 0.001), and lower LVEDD (*P* < 0.001) and TAPSE (*P* = 0.037). On the other hand, in patients with ATTR CA, LQRSV were less common in those with NAC staging = 1 (*P* = 0.048) and more common in those with atrial fibrillation (*P* = 0.013), anterior pseudoinfarction QRS pattern (*P* = 0.015), lower LV mass (*P* = 0.029), pericardial effusion (*P* = 0.005), and lower TAPSE (*P* = 0.005). Using a penalized GLM analysis, LQRSVs were independently associated with younger age, higher NYHA functional class and

**TABLE 1** Baseline Characteristics of the Overall Population Based on the CA Subtype and the Presence of LQRSV

	AL CA				ATTR CA			
	Overall (N = 120)	No LQRSV (n = 54)	LQRSV (n = 66)	P Value	Overall (N = 291)	No LQRSV (n = 188)	LQRSV (n = 103)	P Value
Sex, %	M: 78 (65) F: 42 (35)	M: 37 (69) F: 17 (31)	M: 41 (62) F: 25 (38)	0.50	M: 263 (90) F: 28 (10)	M: 168 (89) F: 20 (11)	M: 95 (92) F: 8 (8)	0.43
Age, y	66 ± 10	68 ± 10	64 ± 10	0.046	77 ± 9	77 ± 10	76 ± 8	0.61
BMI, kg/m <sup>2</sup>	24 ± 3	25 ± 4	24 ± 3	0.39	26 ± 3	26 ± 3	26 ± 3	0.85
PM/ICD	6 (5)	2 (4)	4 (6)	0.57	19 (7)	13 (7)	6 (6)	0.72
NYHA functional class <sup>a</sup>								
II	55 (47)	32 (59)	23 (37)	0.014	176 (62)	112 (61)	64 (64)	0.60
III	36 (31)	7 (13)	29 (46)	<0.001	60 (21)	41 (22)	19 (19)	0.55
IV	5 (4)	1 (2)	4 (6)	0.37	2 (0.7)	1 (1)	1 (1)	1.00
GFR, mL/min	61 ± 30	59 ± 30	64 ± 31	0.52	65 ± 20	67 ± 20	63 ± 20	0.15
NT-proBNP >3,000/BNP >250 <sup>b</sup>		–	–	–	118 (41)	71 (39)	47 (48)	0.17
NT-proBNP >1,800/BNP >400 <sup>b</sup>	74 (62)	27 (50)	47 (73)	0.009	–	–	–	–
NAC ATTR staging								
1		–	–	–	162 (56)	113 (60)	49 (48)	0.048
2		–	–	–	108 (37)	63 (34)	45 (44)	0.14
3		–	–	–	20 (7)	12 (6)	8 (8)	0.88
TTR variant		–	–	–	57 (20)	35 (19)	22 (21)	0.57
Perugini grade <sup>c</sup>								
1		–	–	–	14 (6)	11 (6)	3 (3)	0.26
2		–	–	–	79 (32)	53 (33)	26 (30)	0.58
3		–	–	–	151(61)	95 (60)	56 (64)	0.48
Electrocardiography								
Atrial fibrillation	17 (14)	8 (15)	9 (14)	0.83	92 (32)	50 (27)	42 (41)	0.013
First-degree AV block	23/103 (22)	14/46 (30)	9/57 (16)	0.076	94/197 (48)	62/137 (45)	32/60 (53)	0.30
LBBB	3 (3)	2 (4)	1 (2)	0.59	38 (13)	33 (18)	5 (5)	0.003
LAH	49 (41)	28 (53)	21 (32)	0.017	101 (35)	84 (46)	17 (17)	<0.001
RBBB	16 (13)	13 (24)	3 (5)	0.002	59 (20)	45 (24)	14 (14)	0.039
TWI	39 (33)	18 (33)	21 (32)	0.86	43 (15)	26 (14)	17 (17)	0.52
Anterior pseudoinfarction	47 (39)	11 (20)	36 (55)	<0.001	75 (26)	40 (21)	35 (34)	0.015
Limb QRS score	33 ± 17	47 ± 16	22 ± 6	<0.001	36 ± 15	44 ± 13	22 ± 5	<0.001
Precordial QRS score	75 ± 25	85 ± 26	66 ± 22	<0.001	79 ± 24	84 ± 25	71 ± 20	<0.001
Total QRS score	106 ± 40	130 ± 38	85 ± 28	<0.001	113 ± 33	126 ± 31	91 ± 23	<0.001
Echocardiography								
LA diameter, mm	44 ± 8	45 ± 9	44 ± 7	0.66	46 ± 7	46 ± 7	46 ± 7	0.69
IVSd, mm	16 ± 3	15 ± 3	16 ± 3	0.019	18 ± 3	18 ± 4	17 ± 3	0.11
PWTd, mm	14 ± 3	13 ± 3	14 ± 3	0.036	15 ± 3	16 ± 3	15 ± 3	0.087
LVEDD, mm	44 ± 6	47 ± 6	42 ± 5	<0.001	46 ± 6	46 ± 6	46 ± 6	0.89
RWT	0.60 (0.50-0.74)	0.55 (0.45-0.67)	0.67 (0.57-0.78)	<0.001	0.68 (0.57-0.80)	0.68 (0.56-0.83)	0.67 (0.58-0.76)	0.21
LVMI, g/m <sup>2</sup>	142 (116-168)	144 (118-165)	140 (115-167)	0.64	169 (141-209)	170 (144-216)	166 (133-195)	0.029
Limb voltage-to-mass ratio	0.21 (0.15-0.31)	0.32 (0.22-0.46)	0.16 (0.11-0.21)	<0.001	0.20 (0.14-0.27)	0.24 (0.18-0.33)	0.12 (0.10-0.17)	<0.001
Total voltage-to-mass ratio	0.70 (0.53-0.99)	0.88 (0.68-1.22)	0.60 (0.46-0.73)	<0.001	0.64 (0.52-0.83)	0.70 (0.55-0.87)	0.55 (0.45-0.68)	<0.001
Myocardial volume	135 (112-160)	137 (113-157)	133 (109-159)	0.89	161 (134-199)	162 (138-205)	157 (127-182)	0.063
Pericardial effusion	33 (28)	11 (20)	22 (33)	0.15	40 (14)	18 (10)	22 (22)	0.005
Maximum size, mm	5 (4-7)	6 (4-10)	5 (4 - 6)	0.37	5 (4-9)	5 (4-10)	6 (4-9)	0.74
LVEF, %	56 ± 10	57 ± 11	55 ± 8	0.22	54 ± 10	54 ± 11	54 ± 9	0.54
E/e'	18.3 ± 8.8	16.9 ± 9.3	19.4 ± 8.3	0.18	17.2 ± 7.8	17.2 ± 8.1	16.8 ± 7.1	0.53
TAPSE, mm	19 ± 5	20 ± 4	18 ± 5	0.037	19 ± 4	19 ± 4	17 ± 4	0.033
sPAP, mm Hg	34 ± 11	32 ± 10	36 ± 11	0.078	37 ± 12	37 ± 12	39 ± 12	0.17

Values are n (%), mean ± SD, or median (Q1-Q3). <sup>a</sup>Missing data in AL = 3 and in ATTR = 7. <sup>b</sup>NT-proBNP and BNP in ng/L; missing data in AL n = 2 and ATTR n = 10. <sup>c</sup>Bone scintigraphy done in n = 246 ATTR.

AL = light chain amyloidosis; ATTR = transthyretin amyloidosis; AV = atrioventricular; BMI = body mass index; BNP = B-type natriuretic peptide; CA = cardiac amyloidosis; F = female; GFR = glomerular filtration rate; ICD = implantable cardioverter-defibrillator; IVSd = interventricular septum in diastole; LA = left atrium; LAH = left anterior hemiblock; LBBB = left bundle branch block; LQRSV = low QRS voltage; LVEF = left ventricular ejection fraction; LVEDD = left ventricular end-diastolic diameter; LVMI = left ventricular mass index; M = male; NAC = National Amyloidosis Centre; NT-proBNP = N-terminal pro-B-type natriuretic peptide; NYHA = New York Heart Association; PM = pacemaker; PWTd = posterior wall thickness in diastole; RBBB = right bundle branch block; RWT = relative wall thickness; sPAP = systolic pulmonary artery pressure; TAPSE = tricuspid annular peak systolic excursion; TWI = T-wave inversion.

**TABLE 2 Clinical and Echocardiographic Predictors of LQRSV on 12-Lead ECG Based on Multivariable Penalized Regression Models**

	AL CA			ATTR CA		
	OR	CI	P Value	OR	CI	P Value
Age, y	0.942	0.907-0.984	0.015			
NT-proBNP >3,000/BNP >250 <sup>a</sup>				1.477	0.997-1.887	0.18
NT-proBNP >1,800/BNP >400 <sup>a</sup>	2.992	1.067-6.74	0.041			
LVEF, %				1.012	0.979-1.031	0.40
LVMI, g/m <sup>2</sup>	0.987	0.971-1.017	0.235	0.994	0.91-1.091	0.097
Pericardial effusion				2.812	1.929-4.100	0.008
TAPSE, mm				0.935	0.908-0.991	0.038
NYHA class	2.33	1.242-4.826	0.016	0.802	0.674-1.318	0.38
Atrial fibrillation				1.876	0.757-2.268	0.28
IVSd, mm	1.215	0.80-1.57	0.216			
LVEDD, mm	0.925	0.824-1.047	0.138			

Variables with nonzero coefficients in the penalized generalized linear (binomial, logit link) model. <sup>a</sup>NT-proBNP and BNP in ng/L. Abbreviations as in Table 1.

natriuretic peptides in AL CA, and pericardial effusion and lower TAPSE in ATTR CA (Table 2).

**PROGNOSIS.** During a median follow-up of 33 months (IQR: 21-46), 61 (15%) of 411 patients died of CV causes, 33 (28%, 25 patients with LQRSV) in the AL group and 28 (10%, 16 patients with LQRSV) in the ATTR group (crude percentages). No significant differences in the CV mortality rate were found between ATTR-v and ATTR-wt patients (log-rank  $P = 0.728$ ) (Supplemental Figure 2).

ROC curve analysis showing the capability and best cutoff of multiple measures of QRS voltages and voltage-to-mass ratios in predicting CV mortality are shown in Supplemental Table 2 and Supplemental Figure 3.


In AL amyloidosis, survival curves indicated that at 40 months there was an approximately 90% chance of survival in the non-LQRSV group compared with 60% in the LQRSV group (log-rank  $P = 0.003$ ) (Figure 1A). These findings were confirmed also using a competing risk model including CV and all-cause mortality (Fine and Gray HR: 3.14; 95% CI: 1.46-6.75;  $P = 0.003$ ) (Supplemental Figure 4A). Cox univariable regression analysis showed that LQRSVs were significantly associated with CV mortality (HR: 3.14; 95% CI: 1.41-6.98;  $P = 0.005$ ) and remained so (HR: 1.76; 95% CI: 2.41-10.18;  $P = 0.031$ ), also in a penalized Cox proportional hazards survival model including all variables with nonzero coefficients (Table 3).

In ATTR amyloidosis, at 40 months there was an approximately 95% chance of survival for the non-LQRSV group compared with 80% for the LQRSV group (log-rank  $P = 0.009$ ) (Figure 1B). These findings were confirmed also using a competing risk model including CV and all-cause mortality (Fine and Gray

HR: 2.66; 95% CI: 1.27-5.56;  $P = 0.010$ ) (Supplemental Figure 4B). Cox univariable regression analysis showed that LQRSV were significantly associated with CV mortality (HR: 2.61; 95% CI: 1.23-5.52;  $P = 0.012$ ) and remained so (HR: 2.64; 95% CI: 1.82-20.17;  $P = 0.005$ ), also in a penalized Cox proportional hazards survival model including all variables with nonzero coefficients (Table 3). Survival probabilities by Kaplan-Meier analysis stratified by NAC stage for the ATTR cohort are shown in Figure 2A. At 36 months, stage I patients had a 99% chance of survival, stage II patients 85%, and stage III patients 67% ( $P < 0.001$ ). For this model, the time-dependent AUC was 0.83 (95% CI: 0.77-0.89). The competing risk model including CV and all-cause mortality is shown in Supplemental Figure 5A. By adding LQRSV to the NAC staging system (Figure 2B), significant differences in survival probability were found among stage II versus stage II + LQRSV ( $P = 0.032$ ) but not for stage I versus stage I + LQRSV ( $P = 0.15$ ) and stage III versus stage III + LQRSV ( $P = 0.62$ ). The competing risk model including CV and all-cause mortality is shown in Supplemental Figure 5B. For this model, the time-dependent AUC was 0.87 (95% CI: 0.81-0.93), resulting in a further incremental prognostic accuracy for CV mortality with respect to NAC staging (adjusted Blanche's  $P < 0.001$ ; net reclassification improvement = 0.24) (Figure 3).

**DISCUSSION**

This study was designed to assess the prevalence and clinical predictors of electrocardiographic LQRSV in a large population of patients with CA and investigate their prognostic significance in AL- and ATTR CA subtypes. We reported several important findings



from this multicenter study (Central Illustration). First, LQRSV were overall a common feature (41%) and were significantly more frequent in AL CA (55%) than in ATTR CA (35%). Second, LQRSV were more commonly identified in younger patients with AL CA with increased LV thickness and right ventricular (RV) dysfunction or in patients with ATTR CA with atrial fibrillation, pericardial effusion, lower LV mass, and RV dysfunction. Third, LQRSV were a significant risk factor and independent predictor for CV mortality in both AL- and ATTR CA. Finally, in patients with ATTR CA, LQRSV, when combined with the NAC staging system, provided incremental prognostic accuracy for CV mortality, in particular in those with NAC stage II.

**LQRSV IN CA.** Electrocardiographic LQRSV have been consistently reported as a typical finding of CA.<sup>6,7,15-20,32</sup> Their presence, particularly when combined with a disproportionately increased LV thickness on cardiac imaging, represents 1 of the classic hallmarks of CA, and it is mentioned among the diagnostic red flags for CA according to a recent European consensus document.<sup>8</sup> In previously published series, LQRSV were recorded in 25% to 40% of ATTR CA and in up to 68% of AL CA.<sup>6,32</sup> Our data from a large multicenter database confirmed these earlier observations (ie, LQRSV are common in CA but not ubiquitous and are more prevalent in AL- than ATTR CA subtype despite both conditions sharing a similar pathogenesis and mechanism of amyloid fibril myocardial infiltration). The (mild) discrepancies in LQRSV prevalence in our study compared with

previous studies may be explained by the differences of the method used for the definition of LQRSV, as pointed out by Mussinelli *et al.*<sup>15</sup> In the present study, we used a nadir-to-peak QRS amplitude <5 mm in all limb leads, which is 1 of the most practical and widely used in the clinical setting and has previously demonstrated high values of sensitivity and specificity for CA.<sup>15,32</sup>

**PREDICTORS OF LQRSV IN CA.** Electrocardiographic QRS voltage amplitudes can be altered by multiple conditions that impair either the cardiac generation of electrical signals or their transmission from the heart to body surface.<sup>11,33</sup> In CA, both mechanisms may be implicated in QRS voltage attenuation because chronic amyloid deposition may lead to myocyte death, thereby reducing the “electrically active” myocardium, or act as an electrical insulator, increasing the electrical resistance both within and outside the heart.<sup>19</sup> Nonetheless, amyloid infiltration does not seem to be the only determinant for LQRSV. Indeed, patients with ATTR CA usually present greater LV thickness and LV mass compared with patients with AL CA,<sup>6,34</sup> and this can be hypothesized as being caused by a higher amyloid infiltration burden in ATTR CA. Nevertheless, LQRSV are more common in AL patients, so other pathogenetic mechanisms must be involved. Myocardial inflammation and edema have been recently demonstrated in CA using cardiac magnetic resonance (CMR) imaging,<sup>35</sup> and this finding seems more prominent in untreated AL patients given the well-established direct toxicity of the circulating immunoglobulin ALs to the

**TABLE 3 Analysis of Predictors of CV Mortality in AL CA and ATTR CA**


	Univariable Analysis			Multivariable Analysis		
	HR	95% CI	P Value	HR	95% CI	P Value
<b>AL CA</b>						
Age, y	1.028	0.991-1.067	0.13	1.055	0.995-1.16	0.16
NYHA functional class	6.291	2.881-13.735	<0.001	3.216	3.564-30.938	0.013
GFR, mL/min	1.004	0.990-1.018	0.59			
NT-proBNP >1,800/BNP >400 <sup>a</sup>	6.875	2.088-22.639	0.002			
Peripheral low QRS voltages	3.143	1.414-6.982	0.005	1.759	2.411-10.176	0.031
Anterior pseudoinfarction	1.545	0.780-3.061	0.21			
LA diameter, mm	1.007	0.967-1.047	0.75			
IVSd, mm	1.237	1.082-1.413	0.002	1.35	1.284-2.382	0.040
PWTd, mm	1.098	0.978-1.234	0.11	0.78	0.355-0.765	0.045
LVEDD, mm	0.938	0.879-1.001	0.052			
RWT	8.823	1.244-62.581	0.029			
LVMi, g/m <sup>2</sup>	1.006	0.999-1.013	0.11	1.006	0.971-1.021	0.47
Total voltage-to-mass ratio	0.027	0.001-0.987	0.049			
Pericardial effusion	1.433	0.690-2.974	0.33			
LVEF, %	0.970	0.941-1.000	0.051			
E/e'	1.051	1.013-1.091	0.008			
TAPSE, mm	0.900	0.818-0.989	0.029			
sPAP, mm Hg	1.042	1.009-1.076	0.013			
<b>ATTR CA</b>						
Age, y	1.003	0.964-1.044	0.88	0.965	0.941-1.194	0.63
NYHA functional class	3.709	1.929-7.129	<0.001	1.65	2.401-294.712	0.038
GFR, mL/min	0.988	0.965-1.012	0.34			
NT-proBNP >3,000/BNP >250 <sup>a</sup>	6.539	2.460-17.376	<0.001			
NAC ATTR staging	4.150	2.441-7.054	<0.001	6.945	5.145-150.918	0.006
Peripheral low QRS voltages	2.605	1.230-5.516	0.012	2.643	1.815-20.166	0.005
Anterior pseudonecrosis	0.965	0.410-2.272	0.94	0.414	0.001-2.377	0.21
LA diameter, mm	1.059	1.004-1.118	0.041	0.969	0.941-1.038	0.34
IVSd, mm	1.000	0.901-1.109	0.99	0.968	0.006-0.694	0.08
PWTd, mm	1.030	0.915-1.159	0.62			
LVEDD, mm	1.010	0.948-1.077	0.75			
RWT	1.399	0.194-10.077	0.74			
LVMi, g/m <sup>2</sup>	1.002	0.996-1.007	0.61			
Total voltage-to-mass ratio	0.010	0.001-1.977	0.088			
Pericardial effusion	1.951	0.861-4.423	0.11			
LVEF, %	0.960	0.930-0.992	0.01			
E/e'	1.031	0.986-1.078	0.17			
TAPSE, mm	0.905	0.824-0.994	0.04			
sPAP, mm Hg	1.016	0.987-1.047	0.28			

Variables with nonzero coefficients in the penalized Cox proportional hazard model used to estimate CIs for the multivariable model. <sup>a</sup>NT-proBNP and BNP in ng/L. Abbreviations as in Table 1.

myocardium.<sup>36,37</sup> Moreover, cardiac inflammation characterizes other conditions such as acute myocarditis and takotsubo syndrome in which electrocardiographic LQRSV are frequently observed.<sup>38</sup> Therefore, edema and inflammation may play a role in QRS voltage reduction in AL CA and may be responsible for the more advanced disease stage of our patients with AL CA with LQRSV, characterized as typical by younger age, worse NYHA functional class, higher natriuretic peptide levels, greater LV thickness, and worse RV dysfunction.


Conversely, pathologic mechanisms underlying LQRSV in ATTR seem more complex. Our ATTR patients with LQRSV compared with those without were characterized by similar NYHA functional class, natriuretic peptide levels, and LV systolic and diastolic function but lower LV mass, lower TAPSE, and more frequent atrial fibrillation and pericardial effusion. Some possible explanations can be speculated. Given that patients with ATTR CA are older and more frequently affected by age-related comorbidities such as long-standing arterial hypertension, aortic






stenosis, and metabolic disorders, QRS voltages may likely reflect the hypertrophic remodeling of the heart occurring in these conditions. Alternatively, during the initial phases of amyloid deposition (most of our ATTR patients were in NYHA functional class I or II), hypertrophic compensatory mechanisms in the myocardium able to increase both LV mass and QRS voltages may occur to preserve cardiac performance. On the other hand, LQRSV may be the consequence of

a significant loss of “electrically active” LV myocardium caused by amyloid infiltration-related cell death/apoptosis occurring in the more advanced stages of the disease ([Figure 4](#)). However, CMR and autopsy studies are needed to confirm this hypothesis. Regarding the relationship between LQRSV and TAPSE, a recent CMR study<sup>39</sup> showed that abnormal TAPSE was among the parameters reflecting the highest burden of cardiac amyloid infiltration




**CENTRAL ILLUSTRATION** Prevalence, Predictors, and Prognostic Significance of Low QRS Voltages in Cardiac Amyloidosis



Cipriani A, et al. J Am Coll Cardiol CardioOnc. 2022;4(4):458-470.

Low QRS voltages (LQRSV) are more frequent in light chain cardiac amyloidosis (AL CA) than in transthyretin cardiac amyloidosis (ATTR CA) and are more commonly identified in younger patients with AL CA with a higher New York Heart Association functional class, natriuretic peptides, advanced left ventricular (LV) remodeling and systolic right ventricular (RV) and LV dysfunction or in patients with ATTR CA with atrial fibrillation, pericardial effusion, lower LV mass, and systolic RV dysfunction. Moreover, LQRSVs are a significant risk factor for cardiovascular mortality in both AL- and ATTR CA. NYHA = New York Heart Association; RV = right ventricular; AL = light chain amyloidosis; ATTR = transthyretin amyloidosis; LQRSV = low QRS voltages.



(extracellular volume >70%). Therefore, the consistent association between LQRSV and worse TAPSE in our cohort may reflect an advanced disease stage represented by severe infiltration and cardiomyocyte loss. Finally, pericardial effusion, a well-known marker of advanced disease,<sup>40</sup> played a role as an independent predictor of LQRSV in ATTR, possibly through an electric signal attenuation effect. This finding is in keeping with that of Murtagh *et al*.<sup>20</sup>

**PROGNOSTIC ROLE OF LQRSV IN CA.** In the present study, patients with LQRSV, both with AL CA and ATTR CA, manifested a shorter survival compared with those without LQRSV. Previous work from Kristen *et al*<sup>32</sup> reported that LQRSV were associated with a reduced survival in a smaller cohort of patients with AL CA and in a pooled analysis including AL CA and ATTR CA. Sperry *et al*<sup>19</sup> demonstrated in a U.S.-based study that LQRSV, defined with both limb and Sokolow voltage criteria (S-wave in  $V_1$  plus R-wave in  $V_5$  or  $V_6$   $\leq 15$  mm), predicted all-cause mortality after adjusting for amyloid subtype and other classic predictors of electrocardiographic voltage. Cyrille *et al*<sup>18</sup> reported that a Sokolow index  $\leq 15$  mm was independently associated with adverse outcomes in a cohort of U.S. patients with CA including both AL CA and ATTR CA. Our data add important information to this large cohort that allowed for separate analysis of survival in the 2 subsets of patients. We demonstrated that LQRSV were independent predictors of CV mortality in the 2 CA subsets analyzed separately. Interestingly, in ATTR CA, the integration of LQRSV in the NAC ATTR staging system further increased the

prognostic performance, particularly in patients classified as NAC stage II. We believe that the lack of an adjunctive prognostic discriminative value of LQRSV even in stage III is most probably related to the small number of patients classified in this subgroup; further studies with larger cohorts might highlight the role of LQRSV in more advanced stages of the disease. With the emerging treatment options available for patients with ATTR CA,<sup>41-43</sup> a precise prognostic stratification, in particular for the intermediate-risk patients such as those in NAC stage II group, becomes of crucial importance. Our study results showed that a cost-effective and noninvasive tool like a 12-lead ECG was able to improve risk stratification overall and specifically in these intermediate-risk patients; if validated, our results could help clinicians to better risk stratify patients with ATTR CA and properly select patients who may benefit from new therapeutic strategies.

**STUDY LIMITATIONS.** The major limitations include the retrospective nature of the study and a possible referral bias because of the recruitment of study patients from tertiary centers in Italy. The limited sample size of patients with ATTR-v and the variability in *TTR* variants did not allow further analysis of LQRSV significance in this specific population. Sokolov-Lyon index data have not been collected; however, diagnostic performance of this index was demonstrated to be comparable with the peripheral QRS score.<sup>15</sup> Electrocardiographic machines and filters were not rigorously standardized between centers, even though low-pass filters (which are those

potentially affecting the QRS amplitude the most<sup>44</sup>) were set at 150 Hz in most centers. Among AL patients, an exact estimation of patients who have already started chemotherapy before our first visit was not available. Nevertheless, to date, no case studies demonstrating QRS voltage modifications after therapy in patients with AL CA are reported in the literature. CMR data were not available or standardized enough in most patients, so they were not included in this analysis. Although data regarding cardiac troponin levels have been collected, significant heterogeneity between centers emerged caused by poor standardization and high variability in assays (regular sensitivity or high sensitivity) and troponin type (T or I) use over time, so these data were omitted from the analysis. As a consequence, we could not apply the Mayo Clinic staging system<sup>45</sup> to better characterize the disease severity of our AL patients. Possible relationships between LQRSV occurrence and symptom onset have not been investigated. The relatively low number of adverse events both in AL-CA and ATTR CA may limit the statistical power of the study to rigorously address the prognostic value of LQRSV, even though this is 1 of the largest cohorts presented to date to address this topic.

## CONCLUSIONS

LQRSV were a common but not ubiquitous electrocardiographic pattern in patients with CA and were more prevalent in the AL- than the ATTR CA subtype, thus suggesting distinct pathophysiologic mechanisms. In both AL- and ATTR CA, LQRSV reflected an advanced disease stage and represented an independent risk factor for CV mortality. In patients with ATTR CA, LQRSV provided an incremental

prognostic value over the NAC staging system toward CV mortality in patients with intermediate risk.

**ACKNOWLEDGMENT** This paper was presented at the International Symposium on Amyloidosis, September 7, 2022.

## FUNDING SUPPORT AND AUTHOR DISCLOSURES

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

**ADDRESS FOR CORRESPONDENCE:** Dr Alberto Cipriani, Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua Medical School, Via Giustiniani 2, 35128 Padua, Italy. E-mail: [alberto.cipriani@unipd.it](mailto:alberto.cipriani@unipd.it).

## PERSPECTIVES

**COMPETENCY IN MEDICAL KNOWLEDGE:** LQRSV are a common feature in CA, particularly in AL CA, and they are associated with a more advanced disease stage. Importantly, LQRSV were associated with a worse CV survival in both conditions and were independent predictors of CV death in ATTR CA. In ATTR CA, they provided an incremental prognostic value to the NAC staging system, especially in intermediate-risk patients.

**TRANSLATIONAL OUTLOOK:** Further studies on the hypothesized LQRSV mechanisms, including CMR studies and pathology studies, are needed to further investigate this important electrocardiographic feature. Moreover, larger studies with a standardized inclusion of cardiac biomarkers are necessary to understand the significance of LQRSV when compared and integrated with markers of myocardial injury.

## REFERENCES

1. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. *Lancet*. 2016;387:2641-2654.
2. Westin O, Butt JH, Gustafsson F, et al. Two decades of cardiac amyloidosis: a Danish nationwide study. *J Am Coll Cardiol Cardioonc*. 2021;3:522-533.
3. Nativi-Nicolau J, Siu A, Dispenzieri A, et al. Temporal trends of wild-type transthyretin amyloid cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. *J Am Coll Cardiol Cardioonc*. 2021;3:537-546.
4. Muchtar E, Dispenzieri A, Magen H, et al. Systemic amyloidosis from A (AA) to T (ATTR): a review. *J Intern Med*. 2021;289:268-292.
5. Griffin JM, Rosenblum H, Maurer MS, et al. Pathophysiology and therapeutic approaches to cardiac amyloidosis. *Circ Res*. 2021;128:1554-1575.
6. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. *Circulation*. 2009;120:1203-1212.
7. Rahman JE, Helou EF, Gelzer-Bell R, et al. Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. *J Am Coll Cardiol*. 2004;43:410-415.
8. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. *Eur Heart J*. 2021;42:1554-1568.
9. Rapezzi C, Lorenzini M, Longhi S, et al. Cardiac amyloidosis: the great pretender. *Heart Fail Rev*. 2015;20:117-124.
10. Quarta CC, Perlini S, Longhi S, et al. A simple voltage/mass index improves diagnosis of cardiac amyloidosis: an electrocardiographic and echocardiographic study of 570 patients with left ventricular hypertrophy. *J Am Coll Cardiol*. 2012;59:E1586.
11. Valentini F, Anselmi F, Metra M, et al. Diagnostic and prognostic value of low QRS voltages in cardiomyopathies: old but gold. *Eur J Prev Cardiol*. 2022;29:1177-1187.
12. Porcari A, Rossi M, Cappelli F, et al. Incidence and risk factors for pacemaker implantation in light-chain and transthyretin cardiac amyloidosis. *Eur J Heart Fail*. 2022;24:1227-1236.
13. Palladini G, Milani P, Merlini G. Management of AL amyloidosis in 2020. *Blood*. 2020;136:2620-2627.
14. Kligfield P, Gettes LS, Bailey JJ, et al. Recommendations for the standardization and

- interpretation of the electrocardiogram: part I: the electrocardiogram and its technology: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. *Circulation*. 2007;115:1306-1324.
15. Mussinelli R, Salinaro F, Alogna A, et al. Diagnostic and prognostic value of low QRS voltages in cardiac AL amyloidosis. *Ann Noninvasive Electrocardiol*. 2013;18:271-280.
  16. Cheng Z, Kang L, Tian Z, et al. Utility of combined indexes of electrocardiography and echocardiography in the diagnosis of biopsy proven primary cardiac amyloidosis. *Ann Noninvasive Electrocardiol*. 2011;16:25-29.
  17. Dubrey SW, Bilazarian S, LaValley M, et al. Signal averaged electrocardiography in patients with AL (primary) amyloidosis. *Am Heart J*. 1997;134:994-1001.
  18. Cyrille NB, Goldsmith J, Alvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. *Am J Cardiol*. 2014;114:1089-1093.
  19. Sperry BW, Vranian MN, Hachamovitch R, et al. Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. *Int J Cardiol*. 2016;214:477-481.
  20. Murtagh B, Hammill SC, Gertz MA, Kyle RA, Tajik AJ, Grogan M. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. *Am J Cardiol*. 2005;95:535-537.
  21. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2015;28:1-39. e14.
  22. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging*. 2016;17:1321-1360.
  23. Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using <sup>99m</sup>Tc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. *J Am Coll Cardiol*. 2005;46:1076-1084.
  24. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. *J Clin Oncol*. 2012;30:989-995.
  25. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. *Eur Heart J*. 2018;39:2799-2806.
  26. Nakashima N, Takashio S, Morioka M, et al. A simple staging system using biomarkers for wild-type transthyretin amyloid cardiomyopathy in Japan. *ESC Heart Fail*. 2022;9:1731-1739.
  27. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. *J Stat Softw*. 2010;33:1-22.
  28. Simon N, Friedman J, Hastie T, Tibshirani R. Regularization paths for Cox's proportional hazards model via coordinate descent. *J Stat Softw*. 2011;39:1-13.
  29. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc*. 1999;94:496-509.
  30. Blanche P, Dartigues JF, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. *Stat Med*. 2013;32:5381-5397.
  31. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. *Stat Med*. 2011;30:11-21.
  32. Kristen AV, Perz JB, Schonland SO, et al. Non-invasive predictors of survival in cardiac amyloidosis. *Eur J Heart Fail*. 2007;9:617-624.
  33. Maanja M, Wieslander B, Schlegel TT, et al. Diffuse myocardial fibrosis reduces electrocardiographic voltage measures of left ventricular hypertrophy independent of left ventricular mass. *J Am Heart Assoc*. 2017;6:e003795.
  34. Quarta CC, Solomon SD, Uraizee I, et al. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. *Circulation*. 2014;129:1840-1849.
  35. Kotecha T, Martinez-Naharro A, Treibel TA, et al. Myocardial edema and prognosis in amyloidosis. *J Am Coll Cardiol*. 2018;71:2919-2931.
  36. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. *Circ Res*. 2004;94:1008-1010.
  37. Guan J, Mishra S, Qiu Y, et al. Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. *EMBO Mol Med*. 2014;6:1493-1507.
  38. Perazzolo Marra M, Zorzi A, Corbetti F, et al. Apicobasal gradient of left ventricular myocardial edema underlies transient T-wave inversion and QT interval prolongation (Wellens' ECG pattern) in Tako-Tsubo cardiomyopathy. *Heart Rhythm*. 2013;10:70-77.
  39. Boldrini M, Cappelli F, Chacko L, et al. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. *J Am Coll Cardiol Img*. 2020;13:909-920.
  40. Damy T, Jaccard A, Guellich A, et al. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis. *Amyloid*. 2016;23:194-202.
  41. Griffin JM, Rosenthal JL, Grodin JL, Maurer MS, Grogan M, Cheng RK. ATTR amyloidosis: current and emerging management strategies: JACC: CardioOncology state-of-the-art review. *J Am Coll Cardiol CardioOnc*. 2021;3:488-505.
  42. Emdin M, Aimo A, Rapezzi C, et al. Treatment of cardiac transthyretin amyloidosis: an update. *Eur Heart J*. 2019;40:3699-3706.
  43. Porcari A, Fontana M, Gillmore JD. Transthyretin cardiac amyloidosis. *Cardiovasc Res*. Published online August 5, 2022. <https://doi.org/10.1093/cvr/cvac119>.
  44. Kligfield P, Okin PM. Prevalence and clinical implications of improper filter settings in routine electrocardiography. *Am J Cardiol*. 2007;99:711-713.
  45. Bianchi G, Zhang Y, Comenzo RL. AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: CardioOncology state-of-the-art review. *J Am Coll Cardiol CardioOnc*. 2021;3:467-487.

---

**KEY WORDS** cardiac amyloidosis, echocardiography, electrocardiography, low QRS voltages, prognostic significance, risk stratification

---

**APPENDIX** For an expanded Results section and supplemental tables and figures, please see the online version of this paper.